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Abstract
Introduction: Geriatric patients with a fragility fracture of the hip (FFH) are especially prone to sarcopenia with poor functional
outcomes and quality of life. We assessed the prevalence of sarcopenia in older South African patients with FFH. Risk factors for
sarcopenia were also investigated. Materials and Methods: From August 1 to November 30, 2018, all older patients with FFH
were invited to participate. Sarcopenia was diagnosed based on the revised criteria of the European Working Group on Sar-
copenia in Older People (EWGSOP2). Handgrip strength (HGS) and muscle strength were assessed. Muscle quantity was
determined by dual-energy X-ray absorptiometry. Demographic information was collected, and 25-hydroxyvitamin D (25[OH]D)
status was determined. Results: Of the 100 hip fracture cases, 65 were enrolled, and 52% (34/65) were sarcopenic (women: 62%;
men: 38%). HGS accurately identified sarcopenia (sensitivity and specificity: 100%). Patients >80 years of age had a prevalence of
sarcopenia twice (18/21 [83%]) that of younger patients (18/44 [36%]). Women with sarcopenia were smaller than those without
(weight: p < 0.001; height: p < 0.001; body mass index: p ¼ 0.018). Low 25(OH)D was almost universally present, with median
25(OH)D levels significantly lower in the patients with sarcopenia (27 nmol/L [interquartile range {IQR}: 20–39] vs. 40 nmol/L
[IQR: 29–53]). Several risk factors, including advanced age; female sex; a smaller body size, especially among women; limited
physical activity; and low 25(OH)D levels, were identified. Discussion: The accuracy of HGS testing in this cohort underscores
EWGSOP2’s recommendation that muscle strength is key to sarcopenia. Further study and follow-up are required to determine
the clinical relevance of sarcopenia among FFH patients. Conclusion: The prevalence of sarcopenia in our FFH population is high.
Sarcopenia is associated with poor patient outcomes following surgical intervention. Orthopaedic surgeons should therefore be
cognizant of the presentation and associated risk of sarcopenia as our patient populations age.
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Introduction
Sarcopenia is a progressive and generalized skeletal muscle
disorder that is associated with an increased likelihood of
adverse outcomes including falls, fractures, physical disability,
and mortality.1
The European Working Group on Sarcopenia in Older Peo-
ple published a revised operational definition for sarcopenia as
well as changed cutoff points for diagnostic purposes in 2019
(EWGSOP2).1 Low muscle strength is regarded as the primary
parameter of sarcopenia and is deemed the most reliable mea-
sure of muscle function. The diagnosis of sarcopenia is
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confirmed by the presence of low muscle quantity or quality.
To diagnose sarcopenia, the presence of both reduced muscle
strength and reduced muscle quantity or quality are required.
Limited attention has been paid to sarcopenia in the ortho-
paedic literature in the context of hip surgery for fragility frac-
tures of the hip (FFH). This may be due to the absence of a
clearly defined clinical consequence of sarcopenia. Fragility
fractures result from low-velocity trauma caused by mechani-
cal forces that would not ordinarily result in fracture. The
World Health Organization has quantified this as forces equiv-
alent to a fall from a standing height or less.2,3
Sarcopenia is especially common in older people, with
reported prevalence rates ranging between 5% and 13%,4 and
present in up to 44% of patients undergoing orthopaedic sur-
gery.5 A 3-fold increase in the risk of falls, a 4-fold increase in
the risk of disability, and a significant increase in the risk of
postoperative morbidity and mortality6-10 have been ascribed to
sarcopenia. Patients with sarcopenia are particularly vulnerable
in the setting of major physiologic stressors such as trauma,
surgery, or surgical complications.11
Sarcopenia has also been identified as an independent pre-
dictor of both patient expense and hospital costs, especially in a
post-operative setting.12 Evidence indicates that sarcopenia
prolongs in-hospital stay with a mean additional duration of
3 days, with hospitals operating on a negative margin when
patients with sarcopenia are admitted for surgical procedures.12
In addition, older trauma patients with sarcopenia are more
likely to require frail care facilities after discharge from hos-
pital, which further adds to the total healthcare costs.13
The incidence rate of FFH appears to be stabilizing in more
developed countries14; however, it is projected that the burden
of FFH will shift to developing countries such as Latin Amer-
ica, Asia, and Africa. A recent multicenter, multi-ethnic study
conducted in South Africa confirmed a significant increase in
the incidence rate of hip fractures, with a current incidence rate
of 68.6 per 100 000.15 It is predicted that in 2050, 70% of over
6-million predicted fractures worldwide will occur in develop-
ing countries such as South Africa.14
Therefore, the primary objective of this single-center study
was to determine the prevalence of sarcopenia following hip
surgery for FFH in older patients at a tertiary hospital in South
Africa. Potential risk factors for sarcopenia were sought as a
secondary objective.
Materials and Methods
Study Design and Setting
The study followed a descriptive, cross-sectional design. The
study population included patients admitted to the Division of
Orthopaedic Surgery at Tygerberg Hospital with FFH from
August 1, 2018, to November 30, 2018, who underwent hip
surgery. Tygerberg Hospital is a tertiary level hospital that
serves as a referral center for more than 3.4 million people
residing in the Cape Town Metropole. All patients admitted
with FFH were eligible for inclusion in the study provided that
written informed consent could be obtained. Patients were
excluded if the hip fracture was deemed to be traumatic or
pathological, in the case of acute concomitant illness, and if
they refused a dual-energy X-ray absorptiometry (DXA) study.
The research complied with the World Medical Association
Declaration of Helsinki ethical principles for medical research
involving human subjects and was approved by the Stellen-
bosch University Health Research and Ethics Committee
(HREC ref S18/03/065).
Sarcopenia Assessment
The EWGSOP2 proposes a Find-Assess-Confirm-Severity
(FACS) approach across clinical practices and research stud-
ies.1 As sarcopenia was assessed in our total cohort, the case
finding part of the proposed strategy was not required (Figure
1). A physical performance test (e.g., gait speed) was not prac-
tically possible because the recent FFH and the severity of
sarcopenia were not evaluated in the present study.
Sarcopenia was regarded as probable in the presence of low
muscle strength and confirmed in the presence of both low
muscle strength and low muscle quantity.
Muscle strength was assessed by measuring handgrip
strength (HGS) with a Jamar Hydraulic Hand Dynamometer
(JLW Instruments, Chicago, IL). A validated protocol of the
American Society of Hand Therapists was followed.16 HGS
was measured in the sitting position with the elbow flexed at
90 and the wrist in the neutral position. Patients were asked to
apply the maximum HGS with the left and right hands, respec-
tively. The measurements were repeated 3 times for both
hands. A resting interval of 30 s between each measurement
was allowed. The maximum measured HGS of either hand was
used to indicate the patient’s HGS. An HGS of <27 kg in men
and <16 kg in women denotes low muscle strength in keeping
with a diagnosis of sarcopenia.1
The Hologic Discovery QDR system (S/N 87664; software
version 13.4.2:7; Hologic, Marlborough, MA) was employed to
assess muscle quantity. DXA-derived appendicular skeletal
muscle mass (ASM) was used as a surrogate measure of muscle
mass and as a diagnostic criterion. ASM was determined as the
sum of the lean mass (LM) in both the upper and lower limbs.
As little as 50 g of metal may spuriously elevate soft tissue
mass measured by DXA.17 To avoid overestimating LM in the
fractured hip due to the metal implants, a published protocol by
Di Monaco et al. was employed.18 The doubled LM of the non-
fractured lower limb was substituted for the fractured side
(ASM ¼ 2  [LM in non-fractured lower limb] þ LM in both
upper limbs). Reduced muscle quantity was confirmed in the
presence of an ASM of <20 kg in men and <15 kg in women.
To account for differences in body size, the skeletal muscle
mass index (SMI), expressed as ASM/height,2 was calculated
and reported. An SMI of <5.5 kg/m2 for women and <7 kg/m2
for men was regarded as indicative of low muscle quantity
corrected for body size.1
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Patient Data
A standardized interviewer questionnaire and in-patient hospital
records were used to obtain patient information on age, sex, self-
reported ethnicity, the total length of in-hospital stay, and fracture
type. Lifestyle questions addressed current cigarette smoking,
total pack years in smokers, daily alcohol intake (< or 3 units
per day), and degree of mobility (inactive being ambulant indoors
only and active being ambulant outdoors) prior to hospitalization.
Anthropometry included measurement of mass and height with a
calculated body mass index (BMI). All subjects were weighed on
the same balanced beam scale. Height was measured with a Har-
penden stadiometer (Holtain, Crosswell, UK) with a sliding head-
piece to increase the accuracy of the reading. BMI was calculated
as mass divided by height squared in kg/m2.
Biochemistry
Laboratory analyses were performed on-site by the Tygerberg
Hospital National Health Laboratory Service, a South African
National Accreditation System-accredited medical laboratory
service. Biochemistry performed included serum creatinine,
total calcium, albumin, phosphate, magnesium, hemoglobin,
and 25-hydroxyvitamin D (25[OH]D) levels. A Cobas® analy-
zer (Roche, Basel, Switzerland) was used for the measurement
of both serum total calcium (spectrophotometric detection) and
25(OH)D (electrochemiluminescence binding assay). Labora-
tory reference ranges were as follows: normal total calcium
2.15–2.50 mmol/L, and 25(OH)D levels, expressed in nmol/
L, were defined as deficient (<50 nmol/L), insufficient (52.5–
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Figure 1. Find-Assess-Confirm-Severity approach proposed by the EWGSOP2. Figure adapted from Cruz-Jentoft AJ et al. Sarcopenia: Revised
European consensus on definition and diagnosis.1 Steps taken and tests performed in this study highlighted and indicated in bold text. DXA: dual-
energy X-ray absorptiometry; BIA: bio-impedance analysis; CT: computed tomography; MRI: magnetic resonance imaging; SPPB: short physical
performance battery; TUG: timed-up-and-go test.
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Statistical Analyses
Data were analyzed using Statistica version 13 (TIBCO Soft-
ware Inc, Palo Alto, CA), and continuous data were expressed
as means + standard deviation or median (interquartile range,
IQR), depending on the distribution. Categorical data were
expressed as counts and frequencies. Differences between
groups were detected by means of independent t-tests or
Mann-Whitney U tests for continuous data, whilst a Chi-
square test or Fisher’s exact two-tailed test was used to detect
differences between groups for categorical data. An analysis of
variance (ANOVA) was performed to detect differences
between age groups for sarcopenia-specific criteria, with a
Tukey’s post-hoc test to determine the location of differences,
when present. p-values <0.05 were considered significant. The
prevalence of sarcopenia was calculated by determining the
number of patients with sarcopenia in the entire cohort that
presented over the study period.
Results
Of the 100 patients who underwent hip surgery for FFH at
Tygerberg Hospital during the 4-month study period, 65
patients were included in the study (Figure 2).
Sarcopenia Assessment in the Total Cohort
Thirty-four patients in our study cohort (52%) had sarcopenia.
Sarcopenia criteria in the total cohort and in the cohort with and
without sarcopenia are depicted in Table 1. A low HGS was
present in 34/65 (52%) patients. Reduced muscle quantity, as
evidenced by low ASM, was present in 55/65 (85%) of the
study cohort. A diagnosis of sarcopenia was confirmed in 34/
65 (52%) patients with low HGS and low muscle quantity. All
34 patients with low HGS had low muscle quantity, and low
HGS thus identified patients with sarcopenia with 100% sensi-
tivity and 100% specificity. Low muscle quantity was docu-
mented in an additional 21 patients with normal HGS,
representing 68% of the cohort without sarcopenia. In the total
cohort, only 10 patients had both normal HGS and muscle
quantity (15%).
Clinical Characteristics and Biochemistry of the Total
Cohort
The clinical characteristics, hospital stay, fracture type, and
25(OH)D status of the total study cohort and the cohorts with
and without sarcopenia are shown in Table 2. The study pop-
ulation was predominantly female (39/65 [60%]) and had a
mean age of 74 + 10 years (95% confidence interval: 72.1-
76.9). Patients in the sarcopenic group (78 + 10 years) were
significantly older (p¼ 0.002) than those in the non-sarcopenic
group (71 + 8 years); 32% of the cohort was80 years of age.
The prevalence of sarcopenia in this age category was more
than twice (18/21 [83%]) that in the younger age groups (16/44
[36%]). Table 2 shows that of the 34 patients with sarcopenia,
24 (71%) were women, and 10 (29%) were men; sarcopenia
was documented in 24/39 (62%) women and 10/26 (38%) men.
Thirty-one patients in the total study cohort (48%) did not
fulfill the sex-specific criteria for the diagnosis of sarcopenia,
of which 15 were women, and 16 were men. Figure 3 shows the
age- and sex-specific HGS, ASM, and SMI. HGS declined
significantly with age in women, with the most pronounced
decline noted earlier in women (<70 compared to >80 years,
post hoc p ¼ 0.015) (Figure 3A). In both sexes, the mean ASM
was low in all age categories (Figure 3B), while in SMI, a
significant reduction was observed in females in the 70–79-
year and >80-year categories (post-hoc p¼ 0.045) (Figure 3C).
Paents who had hip 
surgery for FFH (n=100)
Paents included in 
study (n=65)
Study procedures:
• Handgrip strength assessment 
• DXA muscle quanty scan
• Demographics & anthropometry
• Biochemistry including calcium and 25(OH)D status
• Fracture subtype
Exclusion criteria (n=35)
• Refused consent/did not aend 
assessment (n=19)
• Deceased (n=11)
• Acute concomitant illness (n=5)
Sarcopenia assessment
Figure 2. Flow chart of the study FFH: fragility fracture of the hip; DXA: dual-energy X-ray absorptiometry; 25(OH)D: 25-hydroxyvitamin D.
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The median duration of hospital stay was similar in the
groups with and without sarcopenia (6 vs. 5 days, respectively;
p ¼ 0.168). Most patients in this cohort presented with an
intracapsular fracture (65%). Patients with extracapsular hip
fractures appeared more likely to be sarcopenic; however, the
likelihood did not reach statistical significance (p ¼ 0.068;
extracapsular: 16/23 [70%] intracapsular: 18/42 [43%]).
Patients with sarcopenia were less active than those without
sarcopenia (p ¼ 0.046). Only a minority of the total cohort
admitted to excessive alcohol intake (3 units daily), and only
30/65 (46%) ever smoked. While excessive alcohol intake was
not more prevalent in the sarcopenic group, the non-sarcopenic
group included more active smokers (p ¼ 0.009).
Significantly smaller body size, represented by lower body
mass (p < 0.001), shorter height (p < 0.001), and a lower BMI
(p ¼ 0.018), was present in women with sarcopenia compared
to those without sarcopenia. A similar trend was also observed
in men; however, the differences in body size parameters
between men with and without sarcopenia did not reach statis-
tical significance.
The median 25(OH)D levels were significantly lower in the
patients with sarcopenia (27 nmol/L [IQR: 20–39]) than those
without sarcopenia (40 nmol/L [IQR: 29–53]). Deficient
25(OH)D status was documented in 28 of the 31 patients
(90%) with sarcopenia in whom a result was available and in
21/30 (70%) patients without sarcopenia. Normal 25(OH)D
levels were recorded in only 4 patients (7%), all without
sarcopenia.
Serum calcium (p¼ 0.04), serum phosphate (p < 0.001), and
albumin levels (p ¼ 0.05) as well as the hemoglobin value
(<0.001) were significantly lower in the cohort with sarcope-
nia. These results are not tabulated.
Discussion
Sarcopenia is common in older people. Geriatric patients with
FFH are especially prone to sarcopenia, with potential adver-
sity in terms of functional outcome and quality of life following
hip surgery.20 This study showed that sarcopenia following
surgery in older South Africans with FFH is common, with a










(n ¼ 31) Sensitivity Specificity
HGS (kg)
Low HGS*, n (%) 34 (52%) 34 (100%) 0 (0%) 1.0
95% CI: 0.9 -
1.0
1.0
95% CI: 0.9 -
1.0
 Women (n ¼ 39) 24 24 0
 Men (n ¼ 26) 10 10 0
Normal HGS, n (%) 31 (48%) 0 (0%) 31 (100%)
DXA muscle quantity expressed as
ASM (kg)
Low ASM**, n (%) 55 (85%) 34 (100%) 21 (68%) 1.0





 Women (n ¼ 39) 39 24 9
 Men (n ¼ 26) 26 10 12
Normal ASM*, n(%) 10 (15%) 0 (0%) 10 (32%)
DXA muscle quantity expressed as
SMI (kg/m2)






 Women (n ¼ 39) 26 19 7
 Men (n ¼ 26) 22 9 13
Normal SMI*, n(%) 17 (26%) 6 (18%) 11 (35%)
Normal HGS and ASM, n (%) 10 (15%) 0 (0%) 10 (32%)
 Women (n ¼ 39) 6 0 6 n/a n/a
 Men (n ¼ 26) 4 0 4
HGS: handgrip strength; CI: confidence interval; DXA: dual-energy X-ray absorptiometry; ASM, appendicular skeletal muscle mass; SMI, skeletal muscle mass
index.
*Low handgrip strength refers to a handgrip strength <16 kg in women <27 kg in men.
**Low ASM refers to an ASM of <15 kg in women and <20 kg in men.
***Low SMI refers to <5.5 kg/m2 for women and <7 kg/m2 for men.
Sarcopenia diagnosis required both low handgrip strength and low ASM.
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prevalence of 52% based on EWGSOP2 criteria, while differ-
ent prevalence figures for women and men were documented
(62% and 38%, respectively). A low HGS identified all cases
with sarcopenia obviating the need for more expensive mod-
alities such as DXA to confirm the diagnosis in our cohort.
Several risk factors, including advanced age (80 years);
female sex; a smaller body size, especially in women; limited
physical activity; and low median 25(OH)D levels, were iden-
tified as significant predictors of the risk for sarcopenia.
Previously published study data on the prevalence of sar-
copenia in FFH patients are summarized in Table 3. The pre-
valence of sarcopenia obtained in European and Asian
population groups following FFH18,20-29 varies considerably,
with prevalence rates ranging between 14.6% and 67.7% in
women and between 12.4% and 95% in men. This variation
may be explained in part by inherent differences in muscle
strength and muscle quantity among people of different ethni-
cities. Different methodologies and diagnostic cutoffs











Age* (years) 74 + 10 78 + 10 71 + 8 0.002
 <70 yr, n (%) 21 (32%) 7 (21%) 14 (45%)
 70–79 yr, n (%) 23 (35%) 9 (26%) 14 (45%) 0.003
 80 yr, n (%) 21 (32%) 18 (53%) 3 (10%)
Sex
 Female, n (%) 39 (60%) 24 (71%) 15 (48%) 0.081
 Male, n (%) 26 (40%) 10 (29%) 16 (52%)
Ma ¼ ss* (kg)
 Women 55 + 17 48 + 9 67 + 19 <0.001
 Men 59 + 15 52 + 10 63 + 16 0.058
Height* (cm)
 Women 156 + 9 152 + 8 162 + 5 <0.001
 Men 166 + 6 163 + 7 168 + 6 0.075
BMI* (kg/m2) 22 + 6 21 + 4 24 + 7 0.013
 Women 23 + 6 21 + 4 25 + 8 0.018
 Men 21 + 5 20 + 4 23 + 5 0.172
Ethnicity, n (%)
 White 20 (31%) 10 (29%) 10 (32%) 0.960
 Black African 4 (6%) 2 (6%) 2 (7%)
 Mixed ancestry 41 (63%) 22 (65%) 19 (61%)
Length of hospital stay** (days) 6 (4–8) 6 (4–9) 5 (3–7) 0.168
Fracture type, n (%)
 Intracapsular (NOF) 42 (65%) 18 (53%) 24 (77%) 0.068
 Extracapsular (IT) 23 (35%) 16 (47%) 7 (23%)
Smoking, n (%)
 Ever smoker 29 (49%) 10 (32%) 19 (68%) 0.009
 Never smoker 30 (51%) 21 (67%) 9 (32%)
 Pack years in smokers** 22 (12–29) 21 (10–28) 24 (12–45) 0.663
Alcohol, n (%)
 <3 U daily 52 (88%) 28 (90%) 24 (86%) 0.861
 3 U daily 7 (12%) 3 (10%) 4 (14%)
Activity level in last 12 months
n (%)
 Inactive (ambulant indoors) 29 (49%) 20 (65%) 9 (32%) 0.046
 Active (ambulant outdoors also) 30 (51%) 11 (35%) 19 (68%)
25(OH)D assessment







 Normal 25(OH)D, n (%) 4 (7%) 0 (0%) 4 (13%)
 Insufficient 25(OH)D, n (%) 8 (13%) 3 (10%) 5 (17%) 0.064
 Deficient 25(OH)D, n (%) 49 (80%) 28 (90%) 21 (70%)
Data are expressed as n (%), mean* + SD, or median** (interquartile range).
BMI: body mass index; NOF: neck of femur fracture; IT: intertrochanteric fracture; 25(OH)D: 25-hydroxy-vitamin D.
Length of hospital stay refers to the number of days spent in hospital following surgery.
Activity and smoking were evaluated in 59 patients, 31 with sarcopenia and 28 without sarcopenia; 25(OH)D levels were tested in 61 patients, 31 with sarcopenia,
and 30 without sarcopenia.
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(normative data) employed by both European and Asian
researchers also contribute to this finding. Most of the
observed variation is noted among European studies per se,
with a more consistent prevalence reported for both sexes in
Asian studies. The Asian Working Group on Sarcopenia’s
(AWGS) diagnostic cutoff points for sarcopenia have been
consistently used in Asian studies since 2014. The AWGS
requires both a low HGS and a low muscle quantity based
on DXA-measured ASM corrected to size (SMI) to diagnose
sarcopenia. The revised EWGSOP2 introduced in 2019 pro-
vides a simple set of diagnostic criteria and specific diagnostic
cutoff points for HGS, muscle quantity, and physical
performance. Similar to the AWGS, this revised diagnostic
set also requires both HGS and muscle quantity to be low in
order to diagnose sarcopenia. Specific cutoff values for HGS,
however, differ between the AWGS and the revised EWG-
SOP2 criteria. Furthermore, EWGSOP2 allows for either
ASM or SMI to be utilized as a diagnostic index and does not
specifically prescribe correction for body size as does the
AWGS. This makes the comparison between work performed
in Asian populations and populations elsewhere in the world
difficult. A universal set of diagnostic criteria is vital to ensure
uniformity in research outputs and will allow comparison of
findings among studies and different population groups.
Table 3. Available and Published Study Data on the Prevalence of Sarcopenia in Patients With FFH.
Investigators Population Year
Muscle mass
assessment tool Diagnostic criteria Prevalence
Di Monaco et al. Italian 2011 DXA New Mexico Elder Health Study, 1998 58% of women
Di Monaco et al. Italian 2012 DXA New Mexico Elder Health Study, 1998 64% of women
95% of men
Hida et al. Japanese 2013 DXA Japanese criteria (Sanada, 2010) 44.7% of women
81.1% of men
Hong et al. Chinese 2015 DXA Chinese criteria (Cheng, 2014) 41.9% of women
84.1% of men
Di Monaco et al. Italian 2015 DXA New Mexico Elder Health Study, 1998 56% of females
Yoo et al. Korean 2016 DXA AWGS, 2014 44.3% of women
68.2% of men
Ho et al. Hong Kong Chinese 2016 DXA AWGS, 2014 67.7% of women
73.6% of men
González-Montalvo et al. Spanish 2016 Bio-impedance analysis EWGSOP, 2010 18.3% of women
12.4% of men
Steihag et al. Norwegian 2017 Anthropometry EWGSOP, 2010 36.6% of women
Landi et al. Italian 2017 DXA FNIH, 2014 14.6% of women
68.9% of men
Yu-Pin Chen et al. Taiwanese 2019 DXA AWGS, 2014 44.7% of women
63.9% of men
FFH: fragility fracture of the hip; DXA: dual-energy X-ray absorptiometry; AWGS, Asian Working Group for Sarcopenia; EWGSOP, European Working Group on
Sarcopenia in Older People; FNIH, Foundation for National Institutes of Health. Prevalence figures for European studies indicated in normal text, Asian studies
noted in italic font.
Figure 3. (A) Handgrip strength, HGS (kg), (B) appendicular skeletal muscle mass, ASM (kg), and (C) skeletal muscle mass index, SMI (kg/m2)
between female (black circle) and male (gray square) patients for <70, 70–79, and >80 year age categories.
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We defined sarcopenia in the presence of both low HGS and
low muscle mass based on the EWGSOP2 diagnostic cutoff
criteria. DXA-derived ASM was used to categorize patients
as having either normal or low muscle quantity and was also
expressed as SMI; however, the latter was not used to diagnose
sarcopenia. In comparison, HGS measurements are easy and
inexpensive. In our study, all patients diagnosed with sarcope-
nia were accurately and correctly identified with HGS per se
(100% sensitivity and 100% specificity). Considering ASM
only, 20/31 (65%) of the patients without sarcopenia had low
muscle quantity but did not have impaired HGS (specificity
32%). Patients with sarcopenia in our cohort, similar to find-
ings by others,20 had a smaller body size based on mass, height,
and BMI, with significance reached only in women. Correction
of ASM for body size by expressing muscle quantity as SMI in
our study cohort resulted in a decrease in the prevalence of
sarcopenia in the total cohort to 43%. The specificity to cor-
rectly identify sarcopenia when using SMI was 35%, which
was only slightly better than for ASM. Of the 6 patients defined
as not having sarcopenia using SMI, not surprisingly, 5 were
female, and 1 was male, thus, reducing the prevalence of sar-
copenia in women to 49% and in men to 35%. Not correcting
for body size in our patient population may thus result in the
overestimation of the true prevalence of sarcopenia, especially
among our female patients. Utilizing SMI as the only muscle
quantity index should be considered in the future.
In most published work, a higher prevalence of sarcopenia
was noted among men. The higher prevalence of sarcopenia in
men is attributed to older age at presentation with FFH and
poorer general health with more associated comorbidities at
the time of presentation.22 In the most recent study of sarcope-
nia and FFH from Taiwan, sarcopenia was again more preva-
lent among men.20 This contrasts with our findings, where
women were noted to be at increased risk of sarcopenia (62%
vs. 38%). In addition, age was identified as a significant pre-
dictor of sarcopenia in our cohort (p ¼ 0.002), and our female
FFH patients were significantly older than the men (77 + 10
vs. 70 + 9 years; p < 0.003), a finding that may have contrib-
uted to the higher prevalence of sarcopenia among women.
Furthermore, intrinsic factors such as a lower LM and strength
ad initium, which worsens after menopause30 in women com-
pared to men, would also argue for a higher prevalence among
women, as seen by us in this study. However, the association
between sex and sarcopenia has not been fully elucidated.
The 25(OH)D level was low in most of our cohort with FFH,
irrespective of the presence of sarcopenia. However, median
25(OH)D levels were significantly lower in the sarcopenia
cohort (p¼ 0.006), with deficient 25(OH)D levels documented
in 28/31 (90%) patients with sarcopenia in whom the test was
available. Hypovitaminosis D is common in older people and is
even more common in those with skeletal fragility. Low
25(OH)D levels were documented, except for 4 patients in the
non-sarcopenic cohort, in all of our study patients and defi-
ciency noted in 90% of the patients with sarcopenia. 25(OH)D
is the main hormone of bone metabolism with a deficiency
associated with decreased bone mass, impaired mineralization,
and increased risk for skeletal fragility and fractures. Vitamin
D receptors are expressed in many other tissues and are impli-
cated in a variety of biological effects and molecular pathways,
including skeletal muscle function and performance. The asso-
ciation between sarcopenia and hypovitaminosis D has been
noted in a previously published study31 and confirmed in our
cohort. The potential physiological mechanisms for this asso-
ciation have not been fully elucidated; however, the loss of the
positive impact of adequate 25(OH)D on myocyte proliferation
and function32,33 and chronic inflammation due to loss of its
anti-inflammatory effect34 have been implicated in the reduc-
tion of muscle strength and function. Hypovitaminosis D and
the associated increased risk of falls were previously thought to
be only due to skeletal fragility.35 However, current under-
standing has highlighted the direct effect of 25(OH)D on mus-
cle function and mass to explain this association.36,37
Sarcopenia is a predictor of poor outcomes, for example,
higher in-hospital mortality rates, increased postoperative com-
plications, decreased survival, and although not consistently
shown, also an increase in the length of hospital stay.38-41 A
recent study by a Boston group noted that length of stay was
independently correlated with sarcopenia in a group of 91
patients hospitalized following FFH specifically.39 However,
we were unable to confirm this finding in our sarcopenic cohort
(p ¼ 0.168).
In our study, patients with extracapsular hip fractures were
more likely to be sarcopenic (16/23; 70%) than those with
intracapsular fractures (18/42; 43%). Conversely, Di Monaco
et al. reported a lower prevalence of sarcopenia in patients with
extracapsular versus intracapsular hip fractures (50% vs.
64%).25 Patients who sustain intracapsular hip fractures tend
to be more mobile than those sustaining extracapsular frac-
tures,42 which alludes to better physical performance. Further
studies are needed to better define the impact of fracture type
on the risk of sarcopenia in older people.
This study has some limitations. Only 65 patients were
enrolled in this study, and they may not be representative of
the overall geriatric FFH population in South Africa. More-
over, this was a cross-sectional, descriptive study of the pre-
valence and did not include assessment of longer-term
outcomes in those with and without sarcopenia.
The strengths of the study include the fact that a repeatable
definition of sarcopenia was used with a limited chance of
observer bias. Furthermore, an experienced DXA technician
evaluated all the study subjects, thereby ensuring excellent
performance and low intra-operator variability (coefficient of
variation <1%) of the reported DXA measurements. The fact
that 100 patients presented to our facility in a limited time of 4
months bears testimony to the high prevalence and importance
of FFH and associated sarcopenia in older people. We obtained
a 65% response rate in this study. The 35 patients who did not
participate most likely represented a group of patients at
increased risk of associated sarcopenia, and if included, may
have resulted in an even higher prevalence of sarcopenia in our
cohort.
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Conclusions
This study is the first to report on the prevalence of sarcopenia
and associated risk factors in older South Africans after hip
surgery for FFH. We demonstrated that sarcopenia in geriatric
patients with FFH after hip surgery is common, with a preva-
lence of 52%. HGS, an easy and inexpensive measurement, was
identified as a highly sensitive and specific tool to confirm the
diagnosis in our cohort. Advanced age (80 years); female sex;
a smaller body size, especially in women; limited physical
activity; and low 25(OH)D levels were identified as significant
predictors of the risk for sarcopenia.
The loss of lean muscle is associated with impaired perio-
perative outcomes. In a trauma population, sarcopenia is an
insidious disease that needs to be actively excluded. Further
research is needed to determine the medium- to long-term out-
comes of orthopaedic trauma patients with sarcopenia. More-
over, as our patient population ages, at risk patients should be
identified within all other orthopaedic subspecialties.
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